Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | LTK | P29376 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5010808 | 0.98 | KDM4E (0.61) | KDM4EPIM3DAPK3PRKD3MAP4K4 | |
| SCHEMBL7374137 | 0.82 | KDM4E (0.58) | KDM4EPIM3DAPK3PRKD3MAP4K4 | |
| SCHEMBL2192189 | 0.81 | KDM4E (0.47) | KDM4EPIM3DAPK3PRKD3MAP4K4 | |
| SCHEMBL3132502 | 0.80 | KDM4E (0.56) | KDM4EPIM3DAPK3PRKD3MAP4K4 | |
| SCHEMBL1335845 | 0.80 | KDM4E (0.60) | KDM4EALDH1A1GAAPOLBL3MBTL1 | |
| SCHEMBL335081 | 0.80 | KDM4E (0.60) | KDM4EALDH1A1GAAPOLBL3MBTL1 | |
| SCHEMBL5290793 | 0.79 | L3MBTL1 (0.54) | KDM4EPIM3DAPK3PRKD3MAP4K4 | |
| SCHEMBL710321 | 0.79 | KDM4E (0.46) | KDM4EPIM3DAPK3PRKD3MAP4K4 | |
| SCHEMBL27532623 | 0.79 | KDM4E (0.46) | KDM4EPIM3DAPK3PRKD3MAP4K4 | |
| SCHEMBL15774159 | 0.78 | KDM4E (0.58) | KDM4EALDH1A1GAAPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104428294-B | N cycloalkyl N [(heterocyclyl phenyl) methylene] (thio) carboxamide derivative | 拜尔农科股份公司 | 2017-07-14 | — | — | CN | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| EP-1325006-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR | NEUROGEN CORPORATION (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | claimed |
| US-6011053-A | USE TO ELEVATE HDL CHOLESTEROL CONCENTRATIONS, WHICH MAY BE USEFUL IN THE TREATMENT OF ATHEROSCLEROTIC CONDITIONS SUCH AS DYSLIPOPROTEINEMIAS AND CORONARY HEART DISEASE. | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-01-04 | — | — | US | claimed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| CN-111200934-B | Novel agrochemical pesticide composition | 巴斯夫欧洲公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-106489950-B | Reactive compound compound comprising (thio) carboxamide derivative and desinsection, mite killing or eelworm-killing activity compound | 拜耳作物科学股份公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-109169661-A | Composition including biocontrol agent and insecticide | 拜耳作物科学股份公司 | 2019-01-11 | — | — | CN | disclosed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-2004080999-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004041273-A1 | DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3-SULFONYL]-PYRROLIDINE-2-CARBOXYLIC ACID AMIDE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-6653471-B2 | Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction | NEUROGEN CORPORATION | 2003-11-25 | — | — | US | disclosed |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-6011053-A | USE TO ELEVATE HDL CHOLESTEROL CONCENTRATIONS, WHICH MAY BE USEFUL IN THE TREATMENT OF ATHEROSCLEROTIC CONDITIONS SUCH AS DYSLIPOPROTEINEMIAS AND CORONARY HEART DISEASE. | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-01-04 | — | — | US | disclosed |
| WO-1999011618-A1 | SUBSTITUTED INDOLE-1-CARBOTHIOIC ACID AMIDES AS NOVEL ANTIATHEROSCLEROTIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | KDM4E 2087/4885PIM3 4753/4885DAPK3 2384/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | KDM4E 2087/4885PIM3 4753/4885DAPK3 2384/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | KDM4E 3446/4885PIM3 593/4885DAPK3 557/4885 |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | ACACA, ACACB, ACAT1 | KDM4E 2140/4885PIM3 3467/4885DAPK3 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.